Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 344 entries
View as:

A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01758666 Org: User:
Start: 09/30/12 End: 12/31/16 Due: 12/31/17

The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06241066 Org: User:
Start: 01/01/14 End: 10/31/23 Due: 10/31/24

A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04843215 Org: User:
Start: 01/01/21 End: 12/31/26 Due: 12/31/27

Microwave Ablation With Splenic Artery Occlusion for Secondary Hypersplenism

Phase: N/A Priority: Normal
NCT ID: NCT06292715 Org: User:
Start: 01/20/24 End: 12/31/26 Due: 12/31/27

Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06483386 Org: User:
Start: 07/15/24 End: 12/30/26 Due: 12/30/27

Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01637350 Org: User:
Start: 08/31/12 End: 12/31/16 Due: 12/31/17

The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06033482 Org: User:
Start: 06/01/23 End: 12/31/24 Due: 12/31/25

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04797806 Org: User:
Start: 03/12/21 End: 04/30/23 Due: 04/30/24

H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis

Phase: N/A Priority: Normal
NCT ID: NCT05872841 Org: User:
Start: 06/01/23 End: 06/30/25 Due: 06/30/26

Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03121833 Org: User:
Start: 05/01/17 End: 12/20/19 Due: 12/20/20

A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02863367 Org: User:
Start: 08/31/16 End: 12/31/17 Due: 12/31/18

PD1 and PARP for Maintenance Therapy in NSLLC

Phase: N/A Priority: Normal
NCT ID: NCT05392686 Org: User:
Start: 06/20/22 End: 04/01/25 Due: 04/01/26

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06890182 Org: User:
Start: 03/31/25 End: 12/31/27 Due: 12/31/28

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06093438 Org: User:
Start: 11/01/23 End: 07/01/26 Due: 07/01/27

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06454435 Org: User:
Start: 06/30/24 End: 06/30/27 Due: 06/30/28

Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients

Phase: N/A Priority: Normal
NCT ID: NCT05947825 Org: User:
Start: 07/30/23 End: 08/01/24 Due: 08/01/25

Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03398122 Org: User:
Start: 11/14/17 End: 04/01/19 Due: 04/01/20

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05644379 Org: User:
Start: 11/25/22 End: 11/30/25 Due: 11/30/26

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05890287 Org: User:
Start: 05/16/23 End: 10/01/26 Due: 10/01/27

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03359694 Org: User:
Start: 12/31/17 End: 10/31/22 Due: 10/31/23

Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT04842526 Org: User:
Start: 04/12/21 End: 12/31/23 Due: 12/31/24

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Phase: N/A Priority: Normal
NCT ID: NCT06413017 Org: User:
Start: 08/31/23 End: 12/31/25 Due: 12/31/26

Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04128800 Org: User:
Start: 10/31/19 End: 12/31/21 Due: 12/31/22

Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results

Phase: N/A Priority: Normal
NCT ID: NCT06438055 Org: User:
Start: 06/30/24 End: 06/30/26 Due: 06/30/27

Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04582955 Org: User:
Start: 10/30/20 End: 12/31/22 Due: 12/31/23